Trial reportMolecular oncology2017
Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up.
Trial report in Molecular oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer.International journal of molecular sciences · 2021Pooled it
- High-MannoseJournal of proteome research · 2026Article
- Article
- Exploring serumHeliyon · 2024Article
- Age-Related Changes in SerumBiomolecules · 2023Article
- Multiomics insights on the onset, progression, and metastatic evolution of breast cancer.Frontiers in oncology · 2023Review
- High-Throughput Glycomic Methods.Chemical reviews · 2022Review
- Nomograms Based on SerumCurrent oncology (Toronto, Ont.) · 2022Article
- Changes in SerumBiomolecules · 2022Article
- Serum N-glycan profiles differ for various breast cancer subtypes.Glycoconjugate journal · 2021Article
- 5-AZA-dC induces epigenetic changes associated with modified glycosylation of secreted glycoproteins and increased EMT and migration in chemo-sensitive cancer cells.Clinical epigenetics · 2021Article
- Screening and diagnosis of colorectal cancer and advanced adenoma by Bionic Glycome method and machine learning.American journal of cancer research · 2021Article
- Machine Learning Based Analysis of Human SerumCancers · 2020Article
- Hypoxia Alters Epigenetic andFrontiers in oncology · 2020Article
- Sialic Acid Linkage Analysis Refines the Diagnosis of Ovarian Cancer.Frontiers in oncology · 2019Article
- SerumOncotarget · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Using our recently developed high-throughput automated platform, N-glycans from all serum glycoproteins from patients with breast cancer were analysed at diagnosis, after neoadjuvant chemotherapy, surgery, radiotherapy and up to 3 years after surgery. Surprisingly, alterations in the serum N-glycome after chemotherapy were pro-inflammatory with an increase in glycan structures associated with cancer. Surgery, on the other hand, induced anti-inflammatory changes in the serum N-glycome, towards a noncancerous phenotype. At the time of first follow-up, glycosylation in patients with affected lymph nodes changed towards a malignant phenotype. C-reactive protein showed a different pattern, increasing after first line of neoadjuvant chemotherapy, then decreasing throughout treatment until 1 year after surgery. This may reflect a switch from acute to chronic inflammation, where chronic inflammation is reflected in the serum after the acute phase response subsides. In conclusion, we here present the first time-course serum N-glycome profiling of patients with breast cancer during and after treatment. We identify significant glycosylation changes with chemotherapy, surgery and follow-up, reflecting the host response to therapy and tumour removal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.